Investigating genetic influences on late onset Alzheimer's disease
Late Onset Alzheimer's Disease
This study is trying to find out how genetics might affect the risk of developing late onset Alzheimer's disease by looking at families with a history of the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Columbia University Academic / other |
| Locations | 12 sites (Washington D.C., District of Columbia and 11 other locations) |
| Trial ID | NCT05010603 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the genetic factors that may contribute to the risk of late onset Alzheimer's disease (AD). Researchers will recruit families and individuals of diverse ethnic backgrounds who have a family history of AD, focusing on those with multiple affected relatives. The study will involve genetic linkage analysis to identify potential genes associated with increased AD risk, beyond the known susceptibility genes. Participants will undergo blood draws and neuropsychological testing to assess cognitive function and gather relevant data.
Who should consider this trial
Good fit: Ideal candidates include individuals with a diagnosis of late onset Alzheimer's disease or related neurodegenerative disorders, along with family members who have a history of AD.
Not a fit: Patients without a family history of Alzheimer's disease or those who do not meet the specific diagnostic criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of genetic risk factors for Alzheimer's disease, potentially informing prevention and treatment strategies.
How similar studies have performed: Other studies have shown success in identifying genetic factors related to Alzheimer's disease, but this study aims to explore novel genetic influences that have not been previously identified.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent. Exclusion Criteria: * failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Where this trial is running
Washington D.C., District of Columbia and 11 other locations
- University of Washington — Washington D.C., District of Columbia, United States (Recruiting)
- University of Miami — Miami, Florida, United States (Recruiting)
- Rush University — Aurora, Illinois, United States (Recruiting)
- Indiana University — Bloomington, Indiana, United States (Recruiting)
- NCRAD at Indiana University — Indianapolis, Indiana, United States (Recruiting)
- Mayo Clinic — Rochester, Minnesota, United States (Recruiting)
- Joanne Norton — St Louis, Missouri, United States (Recruiting)
- Columbia University Irving Medical Center — New York, New York, United States (Recruiting)
- North Carolina State University — Raleigh, North Carolina, United States (Recruiting)
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States (Recruiting)
- University of Texas Southwestern — Dallas, Texas, United States (Recruiting)
- University of Washington — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Richard P. Mayeux, MD, MSc — Columbia University
- Study coordinator: Dolly Reyes-Dumeyer
- Email: dr2290@cumc.columbia.edu
- Phone: 212-305-5953
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.